NESS ZIONA, Israel, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot ...
GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone ® /Glatopa ® ). PPMS is characterized by continued worsening neurologic function ...
NESS ZIONA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting ...
NESS ZIONA, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
Mapi Pharma is nothing if not persistent. Having tried and failed twice to pull off an IPO on Nasdaq, the Israeli biopharma has arrived on Wall Street yet again in pursuit of $57.5 million (€51.2 ...
Mapi Pharma has closed a $10 million (€9 million) Series A round to finance mid-phase trials of its once-a-month version of Teva's ($TEVA) blockbuster multiple ...
Faster, Simpler, Better: Dramatically Reduce Timelines, Simplify Study Start up, and Increase Quality in Hundreds of Clinical Trials Each Year “This new collaboration with MRT will seek to solve two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results